ARGENX SE

Argenx’s expanded FDA approval of efgartigimod (VYVGART) for all adult generalized myasthenia gravis patients—irrespective of serotype—offers a broader, serotype‑agnostic treatment option, backed by Phase 3 data showing rapid, sustained symptom impr…

FDA expands VYVGART label to all adult generalized myasthenia gravis patients—evidence shows significant, sustained benefit across all serotypes, simplifying treatment and improving access.

Argenx SE’s share price jumped 12 % in the last year thanks to a strong antibody pipeline, growing revenue and better margins, but regulatory delays, clinical risk, and competition may temper this rally.

Argenx’s VYVGART shows rapid, durable relief for MG and CIDP patients, backed by phase‑III data and FDA priority review—redefining neuromuscular treatment options.

Argenx’s sustained share‑price growth hinges on Vyvgart’s CD28 blockade, offering a targeted immunotherapy for lupus and rheumatoid arthritis that could boost investor confidence at the 2026 AGM.

Argenx’s new Phase‑3 data shows VYVGART dramatically improves ocular and generalized myasthenia gravis and expands into CIDP and CMS, offering a potent, convenient SC option with a clear regulatory roadmap.

Argenx’s VYVGART expands into ocular and seronegative myasthenia gravis, showing strong Phase‑3 data and promising CIDP results—positioning the drug for a niche, high‑value market with lower competition.

Argenx SE’s May 2026 AGM will review 2025 results and board changes, spotlighting its high‑margin specialty portfolio, digital therapy plans, and payer‑focused strategies.

Argenx SE’s 2026 AGM reveals board changes, a $25‑$30k FcRn blocker strategy, 10‑year patent window, and M&A plans to sustain growth beyond 2034 patent cliffs.

Argenx’s regulatory setbacks in Europe could slash projected revenue by 41% and erode NPV. Discover how data‑package expansion, outcome‑based pricing, and targeted M&A may salvage growth.